Related Experiment Video
Updated: Sep 10, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
When is it time to bid farewell to anticoagulation?
Julia Czuprynska1, Roopen Arya1
1Department of Haematological Medicine, King's Thrombosis Centre, King's College Hospital NHS Foundation Trust, London, UK.
British Journal of Haematology
|August 22, 2025
Summary
Antithrombotic therapy deprescribing is rare in end-of-life cancer patients. This study highlights the need for greater awareness and shared decision-making interventions for this high-risk patient group.
Area of Science:
- Oncology
- Hematology
- Palliative Care
Background:
- Antithrombotic therapy decisions in end-of-life cancer patients are complex.
- Current prescribing behaviors and outcomes in this population are not well understood.
Purpose of the Study:
- To examine antithrombotic therapy prescribing patterns in cancer patients nearing end of life.
- To investigate the clinical outcomes associated with antithrombotic therapy in this cohort.
- To identify areas for improved patient care and decision-making.
Main Methods:
- A cohort study design was employed.
- Population-linked routinely collected data were utilized for analysis.
- Prescribing behavior and clinical outcomes were examined.
Main Results:
- Deprescribing of antithrombotic therapy was found to be uncommon in this patient group.
- The study identified specific prescribing behaviors and associated clinical outcomes.
- A gap in care regarding deprescribing was observed.
Conclusions:
- Greater awareness of antithrombotic therapy management in end-of-life cancer care is necessary.
- Interventions supporting shared decision-making are required.
- This neglected aspect of care requires focused attention to improve patient outcomes.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
893
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
893
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:30Venous Thrombosis IV: Nursing Management
23
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
23
01:27Pulmonary Embolism III: Nursing Management
38
A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
38
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
44
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
44